More Paradigm Biopharmaceuticals Ltd. news
Paradigm Biopharmaceuticals Ltd.ASX: PAR

Paradigm receives $1.34 million R&D tax incentive rebate

Mar 21, 2017 at 10:46 PM EDT · Issued by Paradigm Biopharmaceuticals Ltd.

Filed with ASX · Mar 21, 2017 at 10:46 PM EDT · 1 page · English

On 6ix: 6ix.com/news/paradigm-receives-dollar1.34-million-randd-tax-incentive-rebate

Paradigm Biopharmaceuticals Ltd. on 6ix

Earlier from Paradigm Biopharmaceuticals

  • Paradigm Update Ross River Virus Clinical TrialMar 7, 2017
  • Quarterly Cashflow ReportJan 31, 2017
  • Recruitment complete in Paradigms hay fever clinical trialJan 24, 2017
  • Paradigms hay fever clinical trial cleared to commenceNov 21, 2016
  • Appendix 4C - September 2016 quarterOct 28, 2016

Later from Paradigm Biopharmaceuticals

  • Final participant treated in Phase 2 hay fever trialMar 22, 2017
  • Paradigm March Quarter Update & Appendix 4CApr 27, 2017
  • Paradigm Government grant for Ross River virus researchMay 10, 2017
  • Paradigms preclinical hay fever trial publishedMay 15, 2017
  • Paradigm Receives Ethics Approval for Ross River TrialMay 21, 2017
All Paradigm Biopharmaceuticals news releases↗

Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.

Follow Paradigm Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer